If a patient with a history of hypertension, atrial fibrillation, or taking anticoagulant medications presents with a large territorial infarct, should it be treated as a hemorrhagic stroke initially?

Management of Large Territorial Infarct: Do NOT Treat as Hemorrhagic Stroke

A large territorial infarct should be managed as an ischemic stroke, not as a hemorrhagic stroke, but with critical modifications to prevent hemorrhagic transformation—specifically, delaying anticoagulation for 14 days in patients with atrial fibrillation and avoiding aggressive blood pressure lowering. 1

Initial Diagnostic Approach

• Immediate CT or MRI is mandatory to confirm the diagnosis of ischemic stroke and exclude hemorrhage before any treatment decisions 2
• The presence of early infarct signs involving more than one-third of the middle cerebral artery territory on CT identifies patients at highest risk for hemorrhagic transformation 3
• Large territorial infarct is defined as: NIHSS score >15, complete arterial territory involvement, or lesions involving >1 arterial territory 1

Critical Management Distinctions from Hemorrhagic Stroke

Blood Pressure Management

• Do NOT aggressively lower blood pressure as you would in intracerebral hemorrhage 2
• Hypertension (systolic >220 mm Hg or diastolic >105 mm Hg) increases hemorrhagic transformation risk, but moderate hypertension may maintain cerebral perfusion 4
• Avoid hypotension, which worsens ischemic injury 4

Anticoagulation Timing (The Most Critical Decision)

For patients with atrial fibrillation and large territorial infarct:

• Delay oral anticoagulation for 14 days after stroke onset to allow blood-brain barrier healing and reduce hemorrhagic transformation risk 1
• Patients with large cerebral infarcts have substantially higher risk of hemorrhagic transformation with early anticoagulation 1, 5
• The recurrent ischemic stroke risk (0.5-1.3% per day) must be balanced against hemorrhagic transformation risk (6-21% with thrombolytics, 1-7% without) 1

If hemorrhagic transformation is detected on follow-up imaging:

• Further delay anticoagulation beyond 14 days until hemorrhage resolves 1
• Patients with early hemorrhagic transformation should delay anticoagulation to allow blood-brain barrier healing 1

Fluid Management

• Use isotonic saline, avoid hypotonic fluids 4
• Maintain normovolemia, not hypervolemia 2
• Avoid fluids with dextrose 4

Glucose Control

• Target glucose <180 mg/dL, avoiding aggressive control (<126 mg/dL) which increases infarct size 4
• Hyperglycemia increases edema and hemorrhagic transformation risk 4

Temperature Management

• Treat fever >37.5°C aggressively 4
• Early fever warrants complete infectious workup 4

Monitoring for Hemorrhagic Transformation

• Repeat CT or MRI at 24-72 hours after stroke onset to assess for hemorrhagic transformation 1, 6
• Clinical deterioration mandates immediate repeat imaging 3
• Validated neurological scales (NIHSS or GCS) should be performed hourly for the first 24 hours 2

Risk Factors for Hemorrhagic Transformation to Monitor

• Large infarct size (>50% MCA territory) carries 6.38-fold increased risk 5
• Previous hemorrhagic stroke increases risk 10.67-fold 5
• Low platelet count (each 10,000 decrease increases risk) 5
• Anticoagulant use at time of stroke 5, 7
• Elevated inflammatory markers (high hsCRP) 5

Common Pitfalls to Avoid

1. Do NOT withhold all antithrombotic therapy indefinitely—the goal is strategic delay, not permanent avoidance 1
2. Do NOT treat blood pressure as aggressively as intracerebral hemorrhage—moderate hypertension may be protective 4
3. Do NOT use dual antiplatelet therapy (aspirin + clopidogrel) chronically after the acute period (maximum 21-30 days) 8
4. Do NOT assume ICP monitoring is beneficial—clinical signs of herniation precede ICP elevation, and monitoring does not improve outcomes in large hemispheric infarcts 9

When Anticoagulation is Eventually Started

• Prefer DOACs over warfarin when anticoagulation is initiated 1, 8
• Apixaban is the preferred DOAC based on superior outcomes 8
• Never combine chronic anticoagulation with antiplatelet therapy unless there is a separate acute vascular indication, and even then limit to 21-30 days maximum 8